Skip to Content

Join the 'Macular Edema' group to help and get support from people like you.

Macular Edema News

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) Prefilled Syringe

Posted 17 Oct 2016 by Drugs.com

South San Francisco, CA – October 14, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO). The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions. “The FDA approval of the Lucentis prefilled syringe marks a new milestone in our ongoing commitment to people affected by vision-threatening eye diseases,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “With the PFS, physicians will have a new option for adm ... Read more

Related support groups: Macular Degeneration, Lucentis, Macular Edema, Ranibizumab

Routine Eye Exams See Vision Problems You Miss

Posted 14 Jul 2016 by Drugs.com

WEDNESDAY, July 13, 2016 – Routine eye checkups often pick up unnoticed problems, particularly in older adults, a new study says. "In asymptomatic patients, comprehensive routine optometric eye examinations detect a significant number of new eye conditions and/or results in management changes," said the study's author, Elizabeth Irving, and her colleagues from the University of Waterloo in Ontario, Canada. More than half of people with no new symptoms or vision problems receive new prescriptions or treatment changes as a result of routine eye exams, the researchers found. The need for vision prescription changes was found for two out of five people, the study noted. Meanwhile, 16 percent were diagnosed with a new eye condition and 31 percent had a change in their ongoing care, researchers found. The study included data on nearly 6,400 patients who visited a university eye clinic over ... Read more

Related support groups: Eye Conditions, Glaucoma, Cataract, Glaucoma (Open Angle), Macular Degeneration, Uveitis, Iritis, Keratitis, Optic Nerve Disorder, Ocular Herpes Simplex, Macular Edema, Corneal Abrasion, Retinal Disorders, Corneal Ulcer, Glaucoma/Intraocular Hypertension, Diagnosis and Investigation, Chorioretinitis, Strabismus, Visual Defect/Disturbance, Chorioditis

Experts Undecided on Whether Seniors Should Get Routine Vision Checks

Posted 1 Mar 2016 by Drugs.com

TUESDAY, March 1, 2016 – There's just not enough good data to say whether or not seniors should be routinely screened for vision trouble by their primary care physicians, an influential panel of U.S. experts reports. The U.S. Preventive Services Task Force (USPSTF) believes current data isn't adequate to assess the potential benefits and harms of such screening in people 65 or older. The task force is an independent, volunteer panel of experts that reviews the scientific evidence and makes recommendations on preventive health services. "We need more evidence on accurate ways to screen for eye conditions in older adults in a primary care setting," task force chair Dr. Al Siu said in a USPSTF news release. Siu is Mount Sinai Health System chair, and a professor in the department of geriatrics and palliative medicine at the Icahn School of Medicine at Mount Sinai, in New York City. ... Read more

Related support groups: Eye Conditions, Cataract, Macular Degeneration, Macular Edema, Diabetic Macular Edema, Visual Defect/Disturbance, Myopia, Color Vision Defect (Acquired)

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found Eylea to be the better choice. The study, funded by the U.S. National Eye Institute (NEI), "will help doctors and their patients with diabetic macular edema choose the most appropriate therapy," study lead author Dr. John Wells said in an institute news release. "The study suggests there is little advantage of choosing Eylea or Lucentis over [much cheaper] Avastin when a patient's loss of visual acuity from macular edema is mild, meaning a visual acuity of 20/40 or better," Wells explained. ... Read more

Related support groups: Eye Conditions, Macular Degeneration, Avastin, Diabetes Mellitus, Lucentis, Macular Edema, Eylea, Bevacizumab, Abnormal Glucose Tolerance, Visual Defect/Disturbance, Diabetic Macular Edema, Ranibizumab, Aflibercept

Carrots Do Help Aging Eyes, Study Shows

Posted 8 Oct 2015 by Drugs.com

THURSDAY, Oct. 8, 2015 – Your parents may have told you, "Eat your carrots, they're good for your eyes," and a new study suggests they were on to something. Pigments called carotenoids – which give red or orange hues to carrots, sweet potatoes and orange peppers, or deep greens to produce like spinach, broccoli and kale – may help ward off the age-linked vision ailment known as macular degeneration, researchers said. While the study can't prove cause-and-effect, one vision care expert wasn't surprised by the findings. "I tell my patients that fruit and vegetable consumption are very important for eye health – this study validates that notion," said Dr. Paul Bernstein, a professor of ophthalmology and visual sciences at the University of Utah School of Medicine in Salt Lake City. Age-related macular degeneration (AMD) is one of the most common causes of vision loss, especially in the ... Read more

Related support groups: Eye Conditions, Dietary Supplementation, Macular Degeneration, Macular Edema, Diabetic Macular Edema, Visual Defect/Disturbance, Carrot Oil

Lucentis Approved for Diabetic Macular Edema

Posted 10 Aug 2012 by Drugs.com

FRIDAY, Aug. 10 – Lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration to treat diabetic macular edema (DME), an eye condition that could threaten a diabetic person's sight, the agency said Friday in a news release. The condition occurs when fluid leaks into the macula, the center of the eye's retina. This leads to macular swelling, causing blurred vision. Diabetes is the leading cause of new cases of blindness among people aged 20 to 74, the FDA said, citing statistics from the U.S. Centers for Disease Control and Prevention. Commonly reported side effects of Lucentis include bleeding of the eye's conjunctiva tissue, eye pain, floaters and increased pressure inside the eye. Lucentis, marketed by San Francisco-based Genentech, was approved previously for wet age-related macular degeneration, and another form of macular edema. More information The ... Read more

Related support groups: Lucentis, Macular Edema

FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion

Posted 23 Jun 2010 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 23, 2010 - Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review. "This approval provides an important new medicine for people experiencing the unexpected vision loss associated with macular edema following RVO," said Hal Barron, M.D., executive vice president, Global Development and chief medical officer. "In the Lucentis RVO clinical trials significantly more people treated with monthly Lucentis showed sustained vision improvement during the six-month study with an effect seen as early as seven days." About the Studies The BRAVO study assessed the safety and efficacy profile of Lucentis in a ... Read more

Related support groups: Macular Degeneration, Lucentis, Macular Edema, Ranibizumab

Drug-Laser Combination Proves Effective For Diabetic Blindness

Posted 28 Apr 2010 by Drugs.com

Drug-Laser Combination Proves Effective For Diabetic blindness [Los Angeles Times] From Los Angeles Times (CA) (April 28, 2010) Apr. 28--For the first time in a quarter of a century, researchers have identified a new treatment for diabetic macular edema, a potentially blinding disorder that affects about 1 million Americans, researchers said Tuesday. The treatment uses a drug called ranibizumab, which when administered in combination with laser phototherapy is twice as effective at reversing vision loss as laser therapy alone. Laser therapy to prevent leakage of blood vessels in the retina has been the gold standard since it was introduced in 1985. The findings were reported online in the journal Ophthalmology. Nearly 50% of those who received both the drug and phototherapy had a visual improvement of at least two lines on an eye chart, compared with 28% of those receiving only ... Read more

Related support groups: Lucentis, Macular Edema, Diabetic Retinopathy, Ranibizumab

Ask a Question

Further Information

Related Condition Support Groups

Diabetic Macular Edema, Eye Conditions

Related Drug Support Groups

fluocinolone, Lucentis, Eylea, Ozurdex, Retisert, Maxidex, Iluvien, Ocu-Dex, AK-Dex, Dexasol, ranibizumab, aflibercept, Decadron Ocumeter